BNTC - ベニテック・バイオファ―マ (Benitec Biopharma Limited) ベニテック・バイオファ―マ

 BNTCのチャート


 BNTCの企業情報

symbol BNTC
会社名 Benitec Biopharma Ltd (ベニテック・バイオファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種    医療関連(Health Care)
概要 事業概要 --   ベニテック・バイオファ―マはオ―ストラリアのバイオ医薬品企業。主に、特定遺伝子の発現を抑制するRNA干渉技術を用いて難病に対する治療法を開発する。遺伝病である眼球咽頭筋ジストロフィ―、またB型肝炎、肺がん、がん関連の神経障害性疼痛などの治療法に焦点を当てる。同社はC型肝炎、HIVやエイズの治療薬メ―カ―へ技術を提供する。本社はメルボルン。   Benitec Biopharma Ltd is an Australian biotechnology company founded in 1997. It is engaged in the development of gene-silencing therapies for the treatment of chronic and life-threatening diseases using DNA-directed RNA interference technology.
本社所在地 F6A/1-15 Barr Street Balmain Sydney New South Wales 2041 AUS
代表者氏名
代表者役職名
電話番号
設立年月日
市場名 NASDAQ Small Cap
ipoyear 2015年
従業員数
url www.benitec.com
nasdaq_url https://www.nasdaq.com/symbol/bntc
adr_tso 2351216
EBITDA EBITDA ー
終値(lastsale) 2.45
時価総額(marketcap) 5760479.2
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 BNTCのテクニカル分析


 BNTCのニュース

   Global RNA Therapeutics Market Growing Impressive Business Opportunities, Industry Trends, Global Demand, Future Scope with Top Players: Quark, Alnylam Pharmaceuticals, Inc Dicerna Pharmaceuticals, Tekmira Pharmaceuticals, Benitec Biopharma, Sanofi  2021/08/13 09:34:24 OpenPR
An influential RNA Therapeutics market report covers an array of factors that have an influence on the market and Pharmaceutical industry which includes industry insight and critical success factors (CSFs), market segmentation and value chain analysis, industry dynamics, drivers, restraints,
   RNAi Therapeutics Market to 2021 is poised to value over US$ 1,209.29 million by 2027 with Leading Key Players: Quark, Olix Pharmaceuticals, Inc., Benitec Biopharma, Rexahn Pharmaceuticals, Inc.  2021/07/08 12:43:21 OpenPR
The RNAi Therapeutics Market was valued at US$ 618.79 million in 2019 and is projected to reach US$ 1,209.29 million by 2027; it is expected to grow at a CAGR of 8.8% from 2020 to 2027. RNAi refers to the
   Benitec Biopharma ADR Earnings Beat, Revenue Misses In Q3 By Investing.com  2021/05/18 00:00:00 Investing.com
Benitec Biopharma ADR Earnings Beat, Revenue Misses In Q3
   Benitec Biopharma Inc Shares Close the Week 27.2% Lower - Weekly Wrap  2021/04/30 22:30:00 Kwhen Finance
Benitec Biopharma Inc (BNTC) shares closed this week 27.2% lower than it did at the end of last week. The stock is currently up 35.7% year-to-date, down 51.8% over the past 12 months, and down 24.8% over the past five years. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 rose 0.1%. Trading Activity Shares traded as high as $5.64 and as low as $4.05 this week.Trading volume this week was 51.0% lower than the 10-day average and 32.6% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 3505.2% The company's stock price performance over the past 12 months lags the peer average by 555.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Benitec Biopharma Inc Shares Close the Week 23.4% Higher - Weekly Wrap  2021/04/23 22:30:00 Kwhen Finance
Benitec Biopharma Inc shares closed this week 23.4% higher than it did at the end of last week. The stock is currently up 82.7% year-to-date, down 49.0% over the past 12 months, and up 1.2% over the past five years. This week, the Dow Jones Industrial Average rose 0.5%, and the S&P 500 rose 1.3%. Trading Activity Shares traded as high as $5.86 and as low as $4.30 this week.Trading volume this week was 35.6% higher than the 10-day average and 46.8% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 2067.6% The company's stock price performance over the past 12 months lags the peer average by 630.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Benitec BioPharma Shares Rally: Technical Levels To Watch  2021/03/23 21:03:02 Benzinga
Benitec BioPharma Inc. (NASDAQ: BNTC ) shares rallied Tuesday following a filing by Morgan Stanley that showed the bank increased its stake in the Australian biotechnology company by 5.2%. The stock gained 190.28% in Tuesday's session, closing at $9.26, and was giving back 11.12% to $8.23 in after-hours trading at last check. Benitec Short-Term Chart Analysis: In the short term, the 5-minute chart above shows three potential key levels. These levels come from the stock's premarket highs. The stock was able to make a high, consolidate and push higher twice during Tuesday’s premarket session. The first … Full story available on Benzinga.com
   BNTC Stock: One Big Investor Has Benitec Biopharma Shares Going Bonkers  2021/03/23 13:38:14 InvestorPlace
Benitec Biopharma (BNTC) stock is rocketing higher in early morning trading on Tuesday after disclosing a new large stake in the company.
   RNAi Therapeutics Market Insight & Future Assessment for the Period – 2027 Analysis Focusing on Update Top Key Players - Alnylam Pharmaceuticals, Inc., Sanofi, Olix Pharmaceuticals, Inc., Glaxosmithkline Plc., Benitec Biopharma, Arbutus Biopharma Corpor  2021/03/05 14:39:40 OpenPR
The RNAi therapeutics market was valued at US$ 618.79 million in 2019 and is projected to reach US$ 1,209.29 million by 2027; it is expected to grow at a CAGR of 8.8% from 2020 to 2027. The report highlights
   Benitec Biopharma Announces Successful Results from the Interim Analysis of the BB-301 Pilot Dosing Study  2021/02/24 13:29:00 PR Newswire
HAYWARD, Calif., Feb. 24, 2021 /PRNewswire/ -- Highlights from the Interim Analysis: Biologically significant, highly-consistent, dose-dependent levels of BB-301 tissue transduction (i.e. delivery of the multi-functional genetic construct into the target pharyngeal muscle cells) BB-301…
   Global RNA Therapeutics Market Growth Factors,Opportunities,Trends Outlook 2021||Quark, Alnylam Pharmaceuticals, Inc Dicerna Pharmaceuticals, Tekmira Pharmaceuticals, Benitec Biopharma  2021/02/09 15:05:28 OpenPR
A persuasive RNA Therapeutics report is an ideal guide to attain an information or key data about market, emerging trends, product usage, and motivating factors for customers, customer preferences, competitor strategies, brand positioning, and customer behavior. The report provides wide-ranging
   Benitec BioPharma Shares Rally: Technical Levels To Watch  2021/03/23 21:03:02 Benzinga
Benitec BioPharma Inc. (NASDAQ: BNTC ) shares rallied Tuesday following a filing by Morgan Stanley that showed the bank increased its stake in the Australian biotechnology company by 5.2%. The stock gained 190.28% in Tuesday's session, closing at $9.26, and was giving back 11.12% to $8.23 in after-hours trading at last check. Benitec Short-Term Chart Analysis: In the short term, the 5-minute chart above shows three potential key levels. These levels come from the stock's premarket highs. The stock was able to make a high, consolidate and push higher twice during Tuesday’s premarket session. The first … Full story available on Benzinga.com
   BNTC Stock: One Big Investor Has Benitec Biopharma Shares Going Bonkers  2021/03/23 13:38:14 InvestorPlace
Benitec Biopharma (BNTC) stock is rocketing higher in early morning trading on Tuesday after disclosing a new large stake in the company.
   RNAi Therapeutics Market Insight & Future Assessment for the Period – 2027 Analysis Focusing on Update Top Key Players - Alnylam Pharmaceuticals, Inc., Sanofi, Olix Pharmaceuticals, Inc., Glaxosmithkline Plc., Benitec Biopharma, Arbutus Biopharma Corpor  2021/03/05 14:39:40 OpenPR
The RNAi therapeutics market was valued at US$ 618.79 million in 2019 and is projected to reach US$ 1,209.29 million by 2027; it is expected to grow at a CAGR of 8.8% from 2020 to 2027. The report highlights
   Benitec Biopharma Announces Successful Results from the Interim Analysis of the BB-301 Pilot Dosing Study  2021/02/24 13:29:00 PR Newswire
HAYWARD, Calif., Feb. 24, 2021 /PRNewswire/ -- Highlights from the Interim Analysis: Biologically significant, highly-consistent, dose-dependent levels of BB-301 tissue transduction (i.e. delivery of the multi-functional genetic construct into the target pharyngeal muscle cells) BB-301…
   Global RNA Therapeutics Market Growth Factors,Opportunities,Trends Outlook 2021||Quark, Alnylam Pharmaceuticals, Inc Dicerna Pharmaceuticals, Tekmira Pharmaceuticals, Benitec Biopharma  2021/02/09 15:05:28 OpenPR
A persuasive RNA Therapeutics report is an ideal guide to attain an information or key data about market, emerging trends, product usage, and motivating factors for customers, customer preferences, competitor strategies, brand positioning, and customer behavior. The report provides wide-ranging

 関連キーワード  (― 米国株 ベニテック・バイオファ―マ BNTC Benitec Biopharma Limited)

 twitter  (公式ツイッターやCEOツイッターなど)